Overview
An Vanhaesebrouck practices in Cambridge, United Kingdom. Vanhaesebrouck is rated as an Elite expert by MediFind in the treatment of Continuous Muscle Fiber Activity Hereditary. Their top areas of expertise are Continuous Muscle Fiber Activity Hereditary, Isaacs' Syndrome, Congenital Myasthenic Syndrome, and Hereditary Ataxia.
Their clinical research consists of co-authoring 37 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 6 articles in the study of Continuous Muscle Fiber Activity Hereditary.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Continuous Muscle Fiber Activity Hereditary
- Isaacs' SyndromeVanhaesebrouck isElite. Learn about Isaacs' Syndrome.
- Advanced
- Congenital Myasthenic SyndromeVanhaesebrouck isAdvanced. Learn about Congenital Myasthenic Syndrome.
- Hereditary AtaxiaVanhaesebrouck isAdvanced. Learn about Hereditary Ataxia.
- Experienced
- Absence SeizureVanhaesebrouck isExperienced. Learn about Absence Seizure.
- Batten DiseaseVanhaesebrouck isExperienced. Learn about Batten Disease.
- CLN1 DiseaseVanhaesebrouck isExperienced. Learn about CLN1 Disease.
- CLN2 DiseaseVanhaesebrouck isExperienced. Learn about CLN2 Disease.
- CLN3 DiseaseVanhaesebrouck isExperienced. Learn about CLN3 Disease.
- CLN4 DiseaseVanhaesebrouck isExperienced. Learn about CLN4 Disease.